Abstract
Tumor hypoxia is a pervasive feature of solid tumors that promotes malignant progression, metastatic dissemination, and resistance to chemotherapy, radiotherapy, and immunotherapy. At the same time, low oxygen tension creates a chemically exploitable vulnerability for selective drug activation. Hypoxia-activated prodrugs (HAPs) and activatable small-molecule theranostics are designed to remain comparatively inactive in oxygenated tissues and to undergo reductase-mediated conversion within hypoxic tumor regions, thereby releasing cytotoxic, targeted, immunomodulatory, or imaging-active species. In this Review, we organize recent advances according to the chemistry of the bioreductive trigger and the mechanism that links reduction to payload release or signal generation. We discuss nitroaromatic and nitroheterocyclic groups, azo linkages, N-oxides, quinones, azides, and redox-active transition-metal complexes, with emphasis on one-electron redox cycling, multielectron reduction, self-immolative fragmentation, and the influence of reduction potential and local oxygen concentration. Representative small-molecule systems are then used to illustrate how hypoxia activation can be integrated with fluorescence and multimodal imaging, phototherapy, immunomodulation, and targeted delivery. Finally, we examine the principal translational barriers including spatial and temporal heterogeneity of tumor oxygenation, reductase dependence, incomplete intratumoral activation, pharmacokinetic limitations, and the need for patient-selection biomarkers and outline design criteria for improving therapeutic index and clinical tractability. Together, these developments position hypoxia-responsive chemistry as a mechanistically tunable platform for precision drug delivery rather than simply a means of targeting oxygen-poor tumor regions.